Portal de Periódicos da CAPES

The Accuracy of the Increased Prostate Specific Antigen Level (Greater than or Equal to 20 Ng./Ml.) in Predicting Prostate Cancer: Is Biopsy Always Required?

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 5 Linguagem: Inglês

10.1016/s0022-5347(05)64279-6

1527-3792

ROBERT E. GERSTENBLUTH, Allen D. Seftel, Nehemia Hampel, Michael G. Oefelein, Martin I. Resnick,

Hepatitis B Virus Studies

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Nov 2002The Accuracy of the Increased Prostate Specific Antigen Level (Greater than or Equal to 20 Ng./Ml.) in Predicting Prostate Cancer: Is Biopsy Always Required? ROBERT E. GERSTENBLUTH, ALLEN D. SEFTEL, NEHEMIA HAMPEL, MICHAEL G. OEFELEIN, and MARTIN I. RESNICK ROBERT E. GERSTENBLUTHROBERT E. GERSTENBLUTH , ALLEN D. SEFTELALLEN D. SEFTEL , NEHEMIA HAMPELNEHEMIA HAMPEL , MICHAEL G. OEFELEINMICHAEL G. OEFELEIN , and MARTIN I. RESNICKMARTIN I. RESNICK View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64279-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Urologists are often referred patients who initially present with an extremely high serum prostate specific antigen (PSA) level. Despite a presumptive diagnosis of prostate cancer, many of these men undergo biopsy to obtain a tissue diagnosis before treatment with androgen ablative therapy. We examined a data base of men undergoing prostate biopsy to determine the accuracy of high PSA levels (greater than or equal to 20 ng./ml.) in predicting prostate cancer. Materials and Methods: We reviewed the records of 1,250 consecutive patients undergoing transrectal ultrasound guided prostate biopsy at 1 institution. From this data base we identified all patients with PSA greater than or equal to 20 ng./ml. at the time of prostate biopsy. The accuracy of PSA in predicting cancer was determined by calculating positive predictive values for PSA ranges and PSA cutoffs. Results: We identified 187 men (15%) presenting with PSA greater than or equal to 20 ng./ml. Of these 187 men 157 (84.0%) were diagnosed with prostate cancer on initial biopsy. Due to a negative initial biopsy, yet a high suspicion of cancer, 12 (6.4%) patients underwent at least 1 repeat biopsy. Of these 12 men 6 (50%) were diagnosed with cancer on repeat biopsy. Overall, 163 of the 187 men (87.2%) were diagnosed with prostate cancer by biopsy. Stratified by PSA ranges, positive predictive values were 73.6% for 20 to 29.9, 90.3% for 30 to 39.9, 93.8% for 40 to 49.9, 100% for 50 to 99.9, 95% for 100 to 199.9 and 100% for greater than or equal to 200 ng./ml. Using PSA cutoffs positive predictive values were 95.7% for PSA greater than or equal to 30, 97.6% for PSA greater than or equal to 40 and 98.5% for PSA greater than or equal to 50 ng./ml. Conclusions: Serum PSA, when increased above 50 ng./ml., is 98.5% accurate in predicting the presence of prostate cancer on tissue biopsy. Nonetheless, since transrectal prostate biopsy has a low complication rate and is relatively well tolerated, we recommend continuing to biopsy most patients with high PSA levels. However, carefully selected elderly patients on chronic anticoagulation, with severe co-morbidities or presenting with spinal cord compression may not require biopsy before androgen ablative therapy since PSA is highly accurate in diagnosing prostate cancer at levels greater than 50 ng./ml. References 1 : National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology1998; 52: 444. Crossref, Medline, Google Scholar 2 : Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med1987; 317: 909. Crossref, Medline, Google Scholar 3 : Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol1995; 154: 407. Link, Google Scholar 4 : Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer1991; 68: 1592. Crossref, Medline, Google Scholar 5 : Serum prostate specific antigen as a prescreening test for prostate cancer. J Urol1992; 147: 846. Link, Google Scholar 6 : Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology1998; 51: 186. Crossref, Medline, Google Scholar 7 : Serum prostate-specific antigen as a surrogate for the histological diagnosis of prostate cancer. S Afr Med J2001; 91: 685. Medline, Google Scholar 8 : Effect of transurethral indwelling catheter on serum prostate-specific antigen level in benign prostatic hyperplasia. Urology1997; 49: 50. Crossref, Medline, Google Scholar 9 : The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol1988; 62: 584. Crossref, Medline, Google Scholar 10 : Characteristics of prostatic infarcts and their effect on serum prostate-specific antigen and prostatic acid phosphatase. Urology1994; 44: 71. Crossref, Medline, Google Scholar 11 : Acute and chronic retention of urine: relevance of raised serum prostatic acid phosphatase levels. A prospective study. Urology1986; 27: 34. Crossref, Medline, Google Scholar 12 : Prostatic infarction. Role in acute urinary retention. Urology1974; 3: 345. Crossref, Medline, Google Scholar 13 : Measurement of prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol1995; 153: 1004. Link, Google Scholar 14 : An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol1993; 149: 783. Link, Google Scholar 15 : The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol1992; 147: 817. Link, Google Scholar 16 : Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology1989; 33: 465. Crossref, Medline, Google Scholar 17 : Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate1992; 20: 105. Crossref, Medline, Google Scholar 18 : Correlation between inflammatory cells (T and B lymphocytes, macrophages) in prostate biopsies and elevated PSA levels in a PSA screening population. Urology2002; 59: 68. Crossref, Medline, Google Scholar 19 : Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol1997; 157: 1301. Link, Google Scholar 20 : Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol2000; 37: 404. Crossref, Medline, Google Scholar 21 : Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol2000; 37: 537. Crossref, Medline, Google Scholar 22 : Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate1994; 25: 91. Crossref, Medline, Google Scholar 23 : Trends and risk factors for prostate biopsy complications in the pre-PSA and PSA eras, 1980 to 1997. Urology2002; 59: 79. Crossref, Medline, Google Scholar From the Cleveland Veterans Affairs Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byWei J, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine S, Han M, Kim S, Kirkby E, Konety B, Miner M, Moses K, Nissenberg M, Pinto P, Salami S, Souter L, Thompson I and Lin D (2023) Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate BiopsyJournal of Urology, VOL. 210, NO. 1, (54-63), Online publication date: 1-Jul-2023. Kim M and Park S (2021) Biparametric Magnetic Resonance Imaging‐Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index LesionJournal of Magnetic Resonance Imaging, 10.1002/jmri.27841, VOL. 55, NO. 4, (1226-1233), Online publication date: 1-Apr-2022. Chinnappan S, Chandra P, Kumar J, Chandran G and Nath S (2021) SUVmax/ADC ratio as a molecular imaging biomarker for diagnosis of biopsy-naïve primary prostate cancerIndian Journal of Nuclear Medicine, 10.4103/ijnm.ijnm_62_21, VOL. 36, NO. 4, (377), . Ozorak A, Zumrutbas A, Bingol G, Ozlulerden Y and Ozturk S (2019) Prostate cancer incidence and diagnosis in men with PSA levels >20 ng/ml: is it possible to decrease the number of biopsy cores?The Aging Male, 10.1080/13685538.2019.1620204, VOL. 23, NO. 5, (893-900), Online publication date: 4-Dec-2020. Aksenov L, Gansler T, Sineshaw H, Fedewa S, Yabroff K, Jemal A and Moul J (2020) Prevalence and correlates of non-tissue prostate cancer diagnosis in the United StatesJournal of Geriatric Oncology, 10.1016/j.jgo.2019.11.003, VOL. 11, NO. 5, (885-892), Online publication date: 1-Jun-2020. Temiz M (2017) MR Imaging–guided Strategies for Detection of Prostate Cancer in Biopsy-Naive MenRadiology, 10.1148/radiol.2017171529, VOL. 285, NO. 3, (1052-1053), Online publication date: 1-Dec-2017. Kedem B, Pan L, Zhou W and Coelho C (2016) Interval estimation of small tail probabilities - applications in food safetyStatistics in Medicine, 10.1002/sim.6921, VOL. 35, NO. 18, (3229-3240), Online publication date: 15-Aug-2016. Sheth C, Gill A and Sekhon S (2016) Life-threatening hemorrhage from acquired hemophilia A as a presenting manifestation of prostate cancerJournal of Community Hospital Internal Medicine Perspectives, 10.3402/jchimp.v6.32461, VOL. 6, NO. 4, (32461), Online publication date: 1-Jan-2016. Baack Kukreja J and Messing E (2016) Prostate Cancer in the Elderly Prostate Cancer, 10.1016/B978-0-12-800077-9.00007-4, (63-72), . Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri V, Santoni M, Santini D, Fratino L, Maines F, Testoni S and De Giorgi U (2015) Metabolic syndrome in castration-resistant prostate cancer patients treated with abirateroneThe Prostate, 10.1002/pros.23014, VOL. 75, NO. 12, (1329-1338), Online publication date: 1-Jul-2015. Huh J, Kim B, Kim Y, Kim S and Park K (2015) The Practicality of Targeted Prostate Biopsy Procedures on the Dominant Side of the Tumor Determined by Magnetic Resonance Imaging in Elderly Patients with High Serum Levels of Prostate-Specific AntigenThe World Journal of Men's Health, 10.5534/wjmh.2015.33.3.188, VOL. 33, NO. 3, (188), . Pal R, Maitra N, Mellon J and Khan M (2013) Defining prostate cancer risk before prostate biopsyUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2012.05.012, VOL. 31, NO. 8, (1408-1418), Online publication date: 1-Nov-2013. Mohamed Z, Dominguez-Escrig J, Vasdev N, Bharathan B and Greene D (2013) The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤15 ng/ml and normal digital rectal examination: A 10-year prospective follow-up study of 427 consecutive patientsUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2012.04.005, VOL. 31, NO. 8, (1489-1496), Online publication date: 1-Nov-2013. Nicolaiew N, Ploussard G, Chun F, Xylinas E, Allory Y, Salomon L and de la Taille A (2013) Prediction of the Risk of Harboring Prostate Cancer by a Prebiopsy Nomogram Based on Extended Biopsy ProtocolUrologia Internationalis, 10.1159/000345603, VOL. 90, NO. 3, (306-311), . Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni N, Karakiewicz P, Rigatti P, Montorsi F and Briganti A (2012) National Comprehensive Cancer Network Practice Guidelines 2011: Need for More Accurate Recommendations for Pelvic Lymph Node Dissection in Prostate CancerJournal of Urology, VOL. 188, NO. 2, (423-428), Online publication date: 1-Aug-2012. Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat S, Fisch M, Graefen M, Pummer K and Chun F (2011) A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsyBJU International, 10.1111/j.1464-410X.2011.10584.x, VOL. 109, NO. 11, (1627-1635), Online publication date: 1-Jun-2012. Jang J and Kim Y (2012) Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?Korean Journal of Urology, 10.4111/kju.2012.53.2.82, VOL. 53, NO. 2, (82), . Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, Suardi N, Capitanio U, Salonia A, Shariat S, Perrotte P, Rigatti P, Montorsi F and Karakiewicz P (2011) Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomyBJU International, 10.1111/j.1464-410X.2011.10204.x, VOL. 108, NO. 11, (1769-1775), Online publication date: 1-Dec-2011. Johnson T (2010) Abdominal and back pain in a 65-year-old patient with metastatic prostate cancerJournal of Chiropractic Medicine, 10.1016/j.jcm.2009.12.004, VOL. 9, NO. 1, (11-16), Online publication date: 1-Mar-2010. Chun F, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders P, Huland H, Abbou C, Stillebroer A, van Gils M, Schalken J, Fradet Y, Marks L, Ellis W, Partin A and Haese A (2009) Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy NomogramEuropean Urology, 10.1016/j.eururo.2009.03.029, VOL. 56, NO. 4, (659-668), Online publication date: 1-Oct-2009. Philip J, Manikandan R, Javlé P and Foster C (2009) Prostate cancer diagnosis: should patients with prostate specific antigen >10ng/mL have stratified prostate biopsy protocols?Cancer Detection and Prevention, 10.1016/j.cdp.2008.12.004, VOL. 32, NO. 4, (314-318), Online publication date: 1-Jan-2009. Briganti A, Shariat S, Chun F, Hutterer G, Roehrborn C, Gallina A, Rigatti P, Valiquette L, Montorsi F and Karakiewicz P (2007) Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of originBJU International, 10.1111/j.1464-410X.2007.07005.x, VOL. 100, NO. 3, (528-532), Online publication date: 1-Sep-2007. Bogen K, Keating G, Chan J, Paine L, Simms E, Nelson D and Holly E (2007) Highly elevated PSA and dietary PhIP intake in a prospective clinic-based study among African AmericansProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500941, VOL. 10, NO. 3, (261-269), Online publication date: 1-Sep-2007. Chun F, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, Scattoni V, Borden L, Steuber T, Salonia A, Schlomm T, Latchemsetty K, Walz J, Kim J, Eichelberg C, Currlin E, Ahyai S, Erbersdobler A, Valiquette L, Heinzer H, Rigatti P, Huland H and Karakiewicz P (2018) Development and External Validation of an Extended Repeat Biopsy NomogramJournal of Urology, VOL. 177, NO. 2, (510-515), Online publication date: 1-Feb-2007. Shim H, Lee S, Park H and Ku J (2007) Accuracy of a High Prostate-Specific Antigen Level for Prostate Cancer Diagnosis upon Initial Biopsy in Korean MenYonsei Medical Journal, 10.3349/ymj.2007.48.4.678, VOL. 48, NO. 4, (678), . Briganti A, Chun F, Salonia A, Gallina A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F and Karakiewicz P (2007) Critical Assessment of Ideal Nodal Yield at Pelvic Lymphadenectomy to Accurately Diagnose Prostate Cancer Nodal Metastasis in Patients Undergoing Radical Retropubic ProstatectomyUrology, 10.1016/j.urology.2006.09.008, VOL. 69, NO. 1, (147-151), Online publication date: 1-Jan-2007. Lessard L, Karakiewicz P, Bellon-Gagnon P, Alam-Fahmy M, Ismail H, Mes-Masson A and Saad F (2006) Nuclear Localization of Nuclear Factor-κB p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node MetastasesClinical Cancer Research, 10.1158/1078-0432.CCR-06-0330, VOL. 12, NO. 19, (5741-5745), Online publication date: 1-Oct-2006. Briganti A, Chun F, Salonia A, Gallina A, Farina E, Da Pozzo L, Rigatti P, Montorsi F and Karakiewicz P (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancerBJU International, 10.1111/j.1464-410X.2006.06318.x, VOL. 98, NO. 4, (788-793), Online publication date: 1-Oct-2006. Briganti A, Chun F, Salonia A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F and Karakiewicz P (2006) Validation of a Nomogram Predicting the Probability of Lymph Node Invasion among Patients Undergoing Radical Prostatectomy and an Extended Pelvic LymphadenectomyEuropean Urology, 10.1016/j.eururo.2006.01.043, VOL. 49, NO. 6, (1019-1027), Online publication date: 1-Jun-2006. KARAKIEWICZ P, BENAYOUN S, KATTAN M, PERROTTE P, VALIQUETTE L, SCARDINO P, CAGIANNOS I, HEINZER H, TANGUAY S, APRIKIAN A, HULAND H and GRAEFEN M (2018) DEVELOPMENT AND VALIDATION OF A NOMOGRAM PREDICTING THE OUTCOME OF PROSTATE BIOPSY BASED ON PATIENT AGE, DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE SPECIFIC ANTIGENJournal of Urology, VOL. 173, NO. 6, (1930-1934), Online publication date: 1-Jun-2005. Brnic Z, Gašparov S, Lozo P, Anic P, Patrlj L and Ramljak V (2005) Is quadrant biopsy sufficient in men likely to have advanced prostate cancer? Comparison with extended biopsyPathology & Oncology Research, 10.1007/BF03032404, VOL. 11, NO. 1, (40-44), Online publication date: 1-Mar-2005. Karam J, Shulman M and Benaim E (2004) Impact of training level of urology residents on the detection of prostate cancer on TRUS biopsyProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500695, VOL. 7, NO. 1, (38-40), Online publication date: 1-Mar-2004. Volume 168Issue 5November 2002Page: 1990-1993 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsprostatic neoplasmsprostate-specific antigenMetricsAuthor Information ROBERT E. GERSTENBLUTH More articles by this author ALLEN D. SEFTEL Financial interest and/or other relationship with Abbott, American Medical Systems, Bayer, Lilly ICOS, Pfizer, Sanofi Synthelab. More articles by this author NEHEMIA HAMPEL More articles by this author MICHAEL G. OEFELEIN More articles by this author MARTIN I. RESNICK Financial interest and/or other relationship with Amgen, Bayer, Focus Surgery and Urologix. More articles by this author Expand All Advertisement PDF downloadLoading ...